Injectable drug development is becoming more complex as pharmaceutical companies advance biologics and combination products. Aptar Pharma has introduced a new system-level framework to support this evolving market. The company will collaborate with partners to improve testing and performance insights for injectable delivery systems.
The collaboration framework was made known by Aptar Pharma, a world leader in drug delivery, dosing, protection technologies, and services. The framework consists of system-level testing and performance data packages. Consequently, customers can be able to make better decisions during development process.
The concept capitalizes on Aptar Pharma’s extensive experience in working with pharmaceutical clients. The company has been working with pharmaceutical clients for over a decade in developing respiratory and ophthalmic drugs. Furthermore, Aptar Pharma is continually growing its portfolio of injectable drug development. In light of the growing biologics, vaccines, and combinations, deeper system knowledge is required from pharmaceutical companies. Moreover, there is an ever-evolving trend in USP <382>. The framework assists customers in making considerations at the development stage.
Aptar Pharma Enhances Injectable Delivery System Development
Aptar Pharma’s Injectable business unit has more than 60 years of experience with elastomeric components. It offers various products that can be used in injectable drug delivery devices. In addition to this, the company collaborates with various companies in the injectable supply chain. These include manufacturers of pre-filled syringes (PFS) and other experts from the industry. Through these collaborations, Aptar Pharma is able to offer customers better insights on system performance.
In the conventional practice, the assessment of container-closure systems is carried out on individual components. This could entail coordinating multiple vendors. In addition, it could cause a delay in identifying any issues in the system. The framework developed by Aptar Pharma is a response to these difficulties. The process allows collecting information on interactions among critical components in the system.
“As injectable therapies become more complex with the rise of biologics and combination products, USP <382> places greater emphasis on system-level understanding,” said Audrey Chardonnet, VP Global Market Development, Aptar Pharma Injectables. “Our approach is designed to help customers make more informed development decisions while preserving the flexibility required for different molecules and formats.”
With the help of the company’s partner network, Aptar Pharma prepares data packages on functional performance. This includes CCIT too. Apart from that, they assess the performance of the seals and interaction of components. This information helps the customer make decisions for container closure early on.
Overall, Aptar Pharma’s system-level framework supports pharmaceutical innovation. It provides valuable insights while helping customers develop safe and effective injectable therapies.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
